Pharma

Aurobindo said it does not anticipate that these matters will have a material impact on the its operations or business results.

Sun Pharma shares price today jumped more than 4 per cent in intraday trade. Sun Pharma the previous day reported a nearly four-fold increase in quarterly net profit. Sun Pharma said it had incurred a one-time tax expense of Rs 513 crore - related to changes in US tax rates - in the year-ago period.

Sun Pharmaceutical Industries' total revenue from operations grew 16.3 per cent to Rs 7740 crore.

CARE has said that the government is expected to proceed with its focus on medicines that are available at affordable prices.

RHT Health Trust, which was originally named Religare Health Trust, netted Fortis about 510 million Singapore dollars when it listed in October 2012.

With the government set to present its Interim Budget on February 1, all eyes are on any announcements for the pharma sector.

The company, currently mired in a controversy surrounding the safety of its baby talcum powder, reported overall sales of Rs 5,828 crore ($829 million) in the country for the year, its filing with the Ministry of Corporate Affairs shows.

GSK and Pfizer would combine their consumer health businesses in a joint venture with sales of 9.8 billion pounds ($12.7 billion), 68 per cent-owned by the British company, in an all-equity transaction.

J&J India did not have any immediate comment on the reports of sample seizures by the authorities. On Tuesday, the company said in a statement that the Reuters article, which was published on Friday, "is one-sided, false and inflammatory".

Sun Pharma said its total revenue from operations rose 4.3 per cent to Rs 6,938 crore in the quarter.

Net profit was 266 crore ($36.00 million) in the quarter ended September 30, compared with a profit of Rs 455 crore a year earlier, Lupin said.

Combination drugs are used to improve patients' compliance, as it is easier to get patients to take one drug rather than several.

Analysts said the deal was positive for Aurobindo Pharma, which said it would make the company the second largest generic player in the US by number of prescriptions. Aurobindo Pharma shares closed 9 per cent higher on Thursday. On Friday, the shares were set to close higher for a third session in a row. At the day's highest level, the shares have registered gains of more than 20 per cent.

Aurobindo Pharma share price jumped more than 6 per cent in intraday trade with large volumes after the announcement. Aurobindo Pharma said it will acquire the dermatology and oral solids businesses from Sandoz Inc, USA, a unit of Swiss pharmaceutical company Novartis. Aurobindo Pharma said the deal worth $900 million was expected to close in 2019.

Novartis AG said on Thursday it would sell the dermatology and generic US oral solids portfolios of Sandoz US to Aurobindo Pharma Ltd for $900 million, as the Swiss drug maker looks to focus on higher growth areas. The deal also includes about 300 products and additional development projects of Sandoz and an additional $100 million in performance-based payments, Novartis said.